Hyperhomocysteinemia
Hyperhomocysteinemia is a metabolic condition in which homocysteine levels are elevated. It is identified through these levels rather than by a specific symptom described here, so a person may not notice a distinctive change.
Hyperhomocysteinemia is classified as a metabolic condition.
This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.
What may help
None of these options has good evidence yet. Best evidence first.
1 option:1 not enough evidence
Tai ChipracticeNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
A cross-sectional comparison of 1,176 people found lower plasma Hcy and lower prevalence of hyperhomocysteinemia among Tai Chi practitioners. The adjusted OR for control versus Tai Chi was 3.67, an association that does not establish cause and effect.
Open the Tai Chi page
The expert view shows every study, dose protocol and source.
What may help
Interventions recorded as helping with this condition1 listedThe best we have, but the evidence is still weak
- →PracticesTai ChiCertaintyLowSourceClinical
A cross-sectional comparison of 1,176 people found lower plasma Hcy and lower prevalence of hyperhomocysteinemia among Tai Chi practitioners. The adjusted OR for control versus Tai Chi was 3.67 (95% CI 2.44–5.53), an association that does not establish cause and effect.
Who was studied
- People with a condition
Open Tai ChiStudy result
PSM-adjusted cross-sectional comparison showing lower plasma Hcy and lower hyperhomocysteinemia prevalence in Tai Chi practitioners; adjusted OR for control vs Tai Chi 3.67 (95% CI 2.44–5.53).
What to avoid
Interventions recorded as making it worseNothing in this library is currently recorded as making Hyperhomocysteinemia worse. Coverage is partial, and absence here is not evidence of safety.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Hyperhomocysteinemia is a metabolic condition in which homocysteine levels are elevated. It is identified through these levels rather than by a specific symptom described here, so a person may not notice a distinctive change. It is discussed in relation to folate, vitamin B12, vitamin B6, and betaine from choline.
Evidence-backed options
The options associated with Hyperhomocysteinemia do not all rest on the same kind of evidence. Vitamin B9 (Folate) has the clearest support in a randomized controlled trial involving rural Chinese adults with H-type hypertension, where the finding concerned the relationship between folic acid exposure and change in total homocysteine. Because that population was specific, the result may not apply equally to people with different health conditions or backgrounds.
Tai Chi is supported by a clinical comparison rather than a treatment trial. It was associated with lower plasma homocysteine and a lower prevalence of Hyperhomocysteinemia among practitioners, but this type of comparison cannot establish that Tai Chi itself caused the difference.
Vitamin B12 (Cobalamin), Vitamin B6 (Pyridoxine), Vitamin B2 (Riboflavin), and Choline (Bitartrate) are described mainly through pharmacology references. Their roles converge on pathways involved in homocysteine handling: B12 and B6 are commonly discussed alongside folate, B2 is particularly relevant to people with the MTHFR C677T polymorphism, and choline can act through betaine-related metabolism when folate or B12 pathways are insufficient. These references provide biological and therapeutic context, but are less direct than controlled clinical evidence.
The findings provided do not establish a common treatment duration or how quickly changes should appear. They also do not show whether the options work equally well across all causes of elevated homocysteine. A clinician can help interpret these distinctions for an individual medical condition.
What to avoid
SAM-e is flagged for Hyperhomocysteinemia because, after donating a methyl group, it is metabolized toward homocysteine. This may add to an already elevated homocysteine burden, making unsupervised use a concern in this condition.
The potential concern may be greater when Vitamin B9 (Folate), Vitamin B12 (Cobalamin), or Vitamin B6 (Pyridoxine) status is inadequate, because the rationale specifically identifies these nutrient statuses as relevant to the risk. This is a condition-specific consideration rather than a general statement about SAM-e for every person.
Anyone with Hyperhomocysteinemia considering SAM-e, particularly alongside possible folate, B12, or B6 inadequacy, can discuss the appropriateness of use with a clinician.